Trial Profile
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tovetumab (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- Sponsors MedImmune
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
- 17 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.